Totally agree, impossible to quantify future research and development costs, but it is possible to assume various situations. If AZM remain independent there has to be a research and development program and in coming to any future bottom line figure I would rather make allowances. Concerned that any alteration to the valuation section would break some of the cell to cell links so will make a backup copy first.
Hopefully, once a commercial agreement is signed for Cetilistat the market will at some stage thereafter begin to look at the possible Earnings potential. Thus, to be able to project EPS without referring to the calculator would be a most welcome addition to the Excel documentation. At some time in the future, when convenient with yourself, I look forward to the inclusion of an EPS indicator.
Allianz Se stock quotes
Allianz Se stock charts
Follow this thread
